Multi-molecular marker and device for clinical evaluation of chemotherapy sensitivity of platinum-based drug for ovarian cancer and evaluation method thereof

Abstract

A multi-molecular marker and a device for clinical evaluation of chemotherapy sensitivity of a platinum-based drug for ovarian cancer and an evaluation method are disclosed, chemotherapy response genes simultaneously are screened from multiple data sets, and the predicting effect of the multi-molecular marker can be verified and comprehensively evaluated in dozens of independent data sets, so thatthe potential application value of the multi-molecular marker in evaluation of the chemotherapy sensitivity of the platinum-based drug can be ensured. The multi-molecular marker contains only 16 genes, is easy to use in tests in clinical trials and reduces the cost of the tests. A patient's tumor tissue sample is easily available, and the patient's tumor tissue sample can be directly obtained forgene expression measurement by a needle; the multi-molecular marker is not affected by the batch effect of experiments or the difference of detection platforms; before the multi-molecular marker is used, standardizing treatment of data of multiple samples is not necessary, and the multi-molecular marker is convenient to use. Patient's drug resistance is monitored in real time before and after chemotherapy, so that a clinical personalized treatment plan is performed in time by a doctor, and the situation that the patient's drug resistance is found after multiple rounds of highly toxic drug application can be avoided.

Description

technical field [0001] The invention relates to the technical fields of medical genomics and oncology, in particular to a multimolecular marker for clinically evaluating ovarian cancer chemotherapy sensitivity to platinum drugs, a device and an evaluation method thereof. Background technique [0002] Ovarian cancer is the deadliest type of obstetrical cancer and the fifth leading cause of cancer death among women. Because of its insidious onset, no obvious symptoms in the early stage, rapid spread, early recurrence and high mortality, it poses an increasingly serious threat to women's health and life. There are more than 220,000 new cases of ovarian cancer and 140,000 deaths worldwide each year. Ovarian cancer is the leading cause of death from gynecological malignancies in China. According to the 2011 China Ovarian Cancer Incidence and Mortality Survey, there are 45,000 new ovarian cancer cases and 18,000 deaths per year in China, which is consistent with the global incid...

AI Technical Summary

Problems solved by technology

Several high-throughput expression analysis studies have found that the gene expression profiles in chemotherapy-sensitive and drug-resistant breast cancer, ovarian cancer and other tumor tissues are different, indicating that it should be a group of genes, rather than a gene expression heterogeneity that can affect The efficacy and sensitivity of drugs, the influence of a single gene on chemotherapy sensitivity may be overwhelmed by many factors, the prediction and evaluation of chemotherapy sensitivity based on single gene markers in the early stage is relatively one-sided, and the sensitivity and specificity are often not ideal

Images